Leukemia Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

The market is segmented by Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, and Others), Type of Leukemia and Geography

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

5.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The leukemia therapeutics market is mainly driven by the rising burden of leukemia cases, high unmet medical need for cancer therapy and rising investment in healthcare sectors. According to the American Cancer Society, in the United States there were approximately 61,780 new cases of leukemia in 2019.

Among them, the number of new cases of acute myeloid leukemia (AML) were around 21,450. AML is thus considered as one of the most common types of leukemia in adults. Hnece the overall statistics shows that there is a huge number of people that are prone to suffer from leukemia, and which may directly impact the growth of the market in the forecast period.

Scope of the Report

Leukemia is a burgeoning blood cancer that forms in the bone marrow and eventually leads to the uncontrolled growth of blood cells. Amid other cancer types, Leukemia is emerging as a life impinging threat, globally. Leukemia therapeutic market consists of different therapeutics advised by the physician for the treatment of leukemia.

By Treatment Type
Chemotherapy
Immunotherapy
Targeted Therapy
Others
By Type of Leukemia
Acute Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy is Expected to Register a Significant Growth in the Forecast Years

Based on the treatment type, it is segmented into Chemotherapy, Immunotherapy, Targeted Therapy, and Others. The primary key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. According to the American Cancer Society, in 2019, there was around 22,840 death from leukemia in the United States, that has been reported and leading to the overall growth of the market.

Many companies are also focusing on developing breakthrough products for the treatment of Leukemia in order to maintain their competitive advantage and penetrate new regional markets. Chemotherapy is thus considered as the main treatment option for most individuals with Leukemia. Additionally, the increase in funding for companies involved in the research related to leukemia is expected to boost the studied market.

To understand key trends, Download Sample Report

North America Holds the Largest Share in the Leukemia Therapeutics Market

The leukemia therapeutics market holds the largest share in the North America region due to the presence of high incidence rate, and advancements in the treatment of leukemia. According to American Cancer Society estimates, there were around 10,920 deaths due to acute myeloid leukemia in the United States in the year 2019. The statistics involve a large percentage of the adult population and they require proper medical treatment to increase their life expectancy.

in addition, Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool and emerging economies in these regions.

To understand geography trends, Download Sample Report.

Competitive Landscape

The leukemia therapeutics market is competitive and many of the global players are into the market. For instance - Amgen Inc, AstraZeneca plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Incyte Corp, Johnson & Johnson, Novartis, Pfizer Inc and Sanofi. are providing these products across the globe. Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Leukemia Cases

      2. 4.2.2 High Unmet Need for Cancer Therapy

      3. 4.2.3 Rising Investment in Healthcare Sector

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

      2. 4.3.2 Stringent Regulatory Scenario

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Immunotherapy

      3. 5.1.3 Targeted Therapy

      4. 5.1.4 Others

    2. 5.2 By Type of Leukemia

      1. 5.2.1 Acute Lymphocytic Leukemia

      2. 5.2.2 Acute Myeloid Leukemia

      3. 5.2.3 Chronic Lymphocytic Leukemia

      4. 5.2.4 Chronic Myeloid Leukemia

      5. 5.2.5 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 AstraZeneca plc

      3. 6.1.3 Bristol-Myers Squibb Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Incyte Corp

      6. 6.1.6 Johnson & Johnson

      7. 6.1.7 Novartis International AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Sanofi S.A.

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

** Subject to Availability

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports